MAPT and Alzheimer disease: The loss of basalforebrain cholinergic neurons projecting to the hippocampus and cortex,along with the discovery that cholinesterase inhibitors (ChEIs) improvecognitive abilities in AD patients, led to the development of thefirst pharmacologic treatment for AD-ChEIs: donepezil, galantamine,and rivastigmine.−,  Aiming to not only alleviate symptoms but also alterthe underlying disease processes, research has since shifted towardextra- and intracellular pathological aggregates of fibrillar proteins–amyloidβ (Aβ) and tau protein, respectively.,